Phase 1a/1b Trial of LY3962673 in KRAS G12D-Mutant Solid Tumors

Eli Lilly and Company is evaluating LY3962673—an oral KRAS (G12D) inhibitor—as a monotherapy and in combination with various chemotherapy agents in patients with advanced, unresectable solid tumors. The study comprises a Phase 1a dose-escalation to assess safety and tolerability, followed by a Phase 1b expansion to further explore preliminary antitumor activity, with an anticipated duration of approximately five years.